Details
Stereochemistry | ACHIRAL |
Molecular Formula | C9H10N6O |
Molecular Weight | 218.2153 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 1 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
NC1=C(\N=N\C2=CC=C(O)C=C2)C(N)=NN1
InChI
InChIKey=AYZRKFOEZQBUEA-OUKQBFOZSA-N
InChI=1S/C9H10N6O/c10-8-7(9(11)15-14-8)13-12-5-1-3-6(16)4-2-5/h1-4,16H,(H5,10,11,14,15)/b13-12+
Molecular Formula | C9H10N6O |
Molecular Weight | 218.2153 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 1 |
Optical Activity | NONE |
CAN-508 is an ATP-competitive inhibitor of cyclin-dependent kinase 9 (Cdk9; IC50 = 350 nM) and moderate inhibitor of similar enzymes including Cdk2-cyclin E. In the HT-29 cancer cell line, CAN-508 was observed to attenuate the frequency of the S-phase. Other CAN-508 effects were shown to involve inhibition of mRNA synthesis, induction of p53, inhibition of IL-6 signaling and reduced phosphorylation of both retinoblastoma protein and RNA polymerase II at the C-terminal domain. CAN-508 has been observed to be an effective antitumor and antimetastatic agent by disrupting TNFα signaling. CAN-508 is an inhibitor of Cdk4, cyclin D1 and p70 S6 Kinase. CAN508 inhibits endothelial cell migration and tube formation. In addition, it reduces phosphorylation of the C-terminus of RNA polymerase II and inhibits mRNA synthesis in endothelial cells, in accordance with previous observations that it has high selectivity towards the positive transcriptional regulator P-TEFb. Moreover, CAN-508 reduces expression of vascular endothelial growth factor by several human cancer cell lines. The findings suggest that P-TEFb may be an attractive target for anti-angiogenic therapy.
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL1907605 Sources: https://www.ncbi.nlm.nih.gov/pubmed/17064068 |
20.0 µM [IC50] | ||
Target ID: CHEMBL3116 |
0.35 µM [IC50] | ||
Target ID: CHEMBL1907601 Sources: https://www.ncbi.nlm.nih.gov/pubmed/17064068 |
13.5 µM [IC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Unknown Approved UseUnknown |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/28404924
In xenograft mouse models, CAN-508 (60 mg/kg/dayx10 days) caused 50.8% reduction in xenograft tumors as compared to control on post-treatment day 21.
Route of Administration:
Intraperitoneal
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/17064068
Curator's Comment: CAN-508 significantly reduced cell proliferation in a dose dependent manner in three esophageal adenocarcinoma cell lines in vitro.Significant inhibition of SKGT4 cell proliferation was detected with 72 hours treatment with a dose of 40 um of CAN-508 while a dose of 20 um of CAN-508 was sufficient to inhibit the proliferation of OE33 and FLO-1 cells. https://www.ncbi.nlm.nih.gov/pubmed/28404924
CAN-508 shows antiproliferative effects (IC50 values are 33, 49, 64 and 62 uM for MCF7, HOS, G361, and K562 cells respectively).
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 11:08:23 GMT 2023
by
admin
on
Sat Dec 16 11:08:23 GMT 2023
|
Record UNII |
ZG0O47K626
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
ZG0O47K626
Created by
admin on Sat Dec 16 11:08:23 GMT 2023 , Edited by admin on Sat Dec 16 11:08:23 GMT 2023
|
PRIMARY | |||
|
9859248
Created by
admin on Sat Dec 16 11:08:23 GMT 2023 , Edited by admin on Sat Dec 16 11:08:23 GMT 2023
|
PRIMARY | |||
|
140651-18-9
Created by
admin on Sat Dec 16 11:08:23 GMT 2023 , Edited by admin on Sat Dec 16 11:08:23 GMT 2023
|
PRIMARY | |||
|
DB07731
Created by
admin on Sat Dec 16 11:08:23 GMT 2023 , Edited by admin on Sat Dec 16 11:08:23 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |